Molecular Formula | C17H16ClN3O |
Molar Mass | 313.78 |
Density | 1.328±0.06 g/cm3(Predicted) |
Boling Point | 595.9±50.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 10.92±0.50(Predicted) |
Storage Condition | -20℃ |
In vitro study | AT13148, as a multi-AGC kinase inhibitor, potently inhibit with GI50 values of 1.5 to 3.8 μm cross a selected panel of cancer cell lines with deregulation of PI3K-AKT-mTOR or RAS-RAF pathways. In PTEN-deficient MES-SA cells, AT13148 also inhibit AKT and p70S6K signaling. AT13148, as a multiplex AGC kinase inhibitor, effectively inhibits cancer cell proliferation with GI50 values of 1.5 to 3.8 μm for a selected group of PI3K-AKT-mTOR or RAS-RAF pathway aberrant cancer cell lines. In PTEN-deficient MES-SA cells, AT13148 also inhibited AKT and p70S6K signaling. |
In vivo study | AT13148 (50 mg/kg p.o.) markedly inhibits the activity of both AKT and p70S6K AGC kinases, and subsequently exhibits marked antitumor effects in human tumor xenografts. in human tumor xenografts, AT13148 (50 mg/kg p.o.) the activity of AKT and p70S6K AGC kinases were significantly inhibited and subsequently exhibited a significant anti-tumor effect. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.187 ml | 15.935 ml | 31.869 ml |
5 mM | 0.637 ml | 3.187 ml | 6.374 ml |
10 mM | 0.319 ml | 1.593 ml | 3.187 ml |
5 mM | 0.064 ml | 0.319 ml | 0.637 ml |